Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 123

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 123
---
,265 APOKYN12,820 17,295 27,796 33,944 Trokendi XR11,193 17,086 23,994 33,075 Oxtellar XR11,637 29,516 21,835 56,459 ONAPGO1,604 — 1,604 — Other(1)6,534 7,543 15,113 14,757 Total net product sales157,995 162,538 299,983 300,999 Royalty, licensing and other revenues7,458 5,787 15,294 10,970 Total revenues$165,453 $168,325 $315,277 $311,969 ___________________________________________(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

In the second quarter of 2025, the Company continued to have favorable actual returns experience for Qelbree. As such, the Company changed its estimated provision for product returns based on the most recent experience. Provision for product returns related to prior year sales for the six months period ended June 30, 2025 is approximately 4% of net product sales primarily attributable to Qelbree. Provision for product returns related to prior year sales for the six months period ended June 30, 2024 was approximately 1% of net product sales. 

4. Investments 

Marketable SecuritiesUnrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):June 30, 2025December 31, 2024(unaudited)Corporate, U.S. government agency and municipal debt securitiesAmortized cost$378,087 $384,481 Gross unrealized gains16 89 Gross unrealized losses(218)(289)Total fair value$377,885 $384,281  As of June 30, 2025, all of the Company's unrestricted available-for-sale marketable securities have contractual maturities of one year or less.

As of June 30, 2025, there was no impairment due to credit loss on any available-for-sale marketable securities. 

11

5.    Fair Value of Financial Instruments

The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.The